Send us Feedback

Allon Therapeutics Inc (NPC)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Allon Therapeutics announces private placement
PR Newswire  Apr 16  Comment 
VANCOUVER, April 16, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) announced today that  it plans to complete a brokered private placement equity offering to raise approximately $10.0 million. The placement is substantially committed. The
Allon's Intellectual Property Portfolio Strengthened With Additional U.S. Patent
Marketwire  Nov 30  Comment 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/30/11 -- Allon Therapeutics Inc. (TSX:NPC) announced today that it has been granted a United States patent covering the use of Allon's drug candidates, including its lead product davunetide, and other
Allon's CEO Presenting at BIO Investor Forum
Marketwire  Oct 25  Comment 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/25/11 -- Allon Therapeutics Inc. (TSX:NPC) President and CEO, Gordon McCauley, will present an update of the Company's business progress on Wednesday, October 26 at the 10th Annual BIO Investor Forum
Allon Granted Important U.S. Patent for Preclinical Compound AL-408
Marketwire  Sep 28  Comment 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 09/28/11 -- Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted an important United States patent covering the composition of matter for the D-isomer of NAP (davunetide). The
Allon Therapeutics Provides Pivotal Study Update and Q2 Operating Results
Marketwire  Aug 12  Comment 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 08/12/11 -- Allon Therapeutics Inc. (TSX: NPC) today provided an update on progress in its pivotal clinical trial in progressive supranuclear palsy (PSP) and announced its unaudited operating results for
New Human Imaging Data Support the Neuroprotective Effects of Allon's Davunetide
Marketwire  Jul 19  Comment 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 07/19/11 -- Allon Therapeutics Inc. (TSX: NPC) today announced new findings that 12 weeks of treatment with the Company's lead product davunetide appears to prevent cortical thinning of important parts
Allon Therapeutics Wins National Biotech Award
Marketwire  Jun 6  Comment 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 06/06/11 -- Allon Therapeutics Inc. (TSX: NPC) today announced it will receive the Gold Leaf Award as the Early Stage Company of the Year (Health) from BIOTECanada, Canada's national biotechnology
Canadian earnings declared Friday: InnVest, Stella-Jones, High Arctic, Armtec
Canadian Business  Mar 11  Comment 
TORONTO - Canadian earnings declared Friday: Allon Therapeutics Inc. (TSX:NPC): Year end Dec. 31, 2010, net loss $16.6 million, 21 cents a
Allon Appoints Dr. Michael Gold Chief Medical Officer
Marketwire  Feb 23  Comment 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/23/11 -- Allon Therapeutics Inc. (TSX: NPC) announced today the appointment of Dr. Michael Gold, M.Sc., M.D. as Vice President, Clinical Development and Chief Medical Officer. Gold joins Allon
Allon Granted Key Japanese Patent for Davunetide
Marketwire  Feb 10  Comment 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/10/11 -- Allon Therapeutics Inc. (TSX: NPC) announced today that an important Japanese patent has been issued covering the composition of matter of the company's lead product davunetide and other




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Allon_Therapeutics_Inc_(NPC)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki